Investigation of Newly Diagnosed Drug-Naive Patients with Systemic Autoimmune Diseases Revealed the Cleaved Peptide Tyrosine Tyrosine (PYY 3-36) as a Specific Plasma Biomarker of Rheumatoid Arthritis
There is a current imperative to reveal more precisely the molecular pathways of early onset of systemic autoimmune diseases (SADs). The investigation of newly diagnosed drug-naive SAD patients might contribute to identify novel disease-specific and prognostic markers. The multiplex analysis of 30 p...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2021/5523582 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849397220682498048 |
|---|---|
| author | Jozsef A. Balog Agnes Kemeny Laszlo G. Puskas Szilard Burcsar Attila Balog Gabor J. Szebeni |
| author_facet | Jozsef A. Balog Agnes Kemeny Laszlo G. Puskas Szilard Burcsar Attila Balog Gabor J. Szebeni |
| author_sort | Jozsef A. Balog |
| collection | DOAJ |
| description | There is a current imperative to reveal more precisely the molecular pathways of early onset of systemic autoimmune diseases (SADs). The investigation of newly diagnosed drug-naive SAD patients might contribute to identify novel disease-specific and prognostic markers. The multiplex analysis of 30 plasma proteins in 60 newly diagnosed drug-naive SADs, such as RA (rheumatoid arthritis, n=31), SLE (systemic lupus erythematosus, n=19), and SSc (systemic scleroderma, n=10) patients, versus healthy controls (HCs, n=40) was addressed. Thirty plasma cytokines were quantified using the Procarta Plex™ panel. The higher expression of IL-12p40, IL-10, IL-13, IFN-γ, M-CSF, IL-4, NTproBNP, IL-17A, BMP-9, PYY (3-36), GITRL, MMP-12, and TNFRSF6 was associated with RA; IL-12p40, M-CSF, IL-4, GITRL, and NTproBNP were higher in SLE; or NTproBNP, PYY (3-36), and MMP-12 were increased in SSc over HCs, respectively. The cleaved peptide tyrosine tyrosine (PYY 3-36) was elevated in RA (361.6±47.7 pg/ml) vs. HCs (163.96±14.5 pg/ml, mean±SEM, ∗∗∗p=4×10−5). The CI (95%) was 268.05-455.16 pg/ml for RA vs. 135.55-192.37 pg/ml for HCs. The elevated PYY (3-36) level correlated significantly with the increased IL-4 or GITRL concentration but not with the clinical scores (DAS28, CRP, ESR, RF, aMCV). We are the first to report cleaved PYY (3-36) as a specific plasma marker of therapy-naive RA. Additionally, the multiplex plasma protein analysis supported a disease-specific cytokine pattern in RA, SLE, and SSc, respectively. |
| format | Article |
| id | doaj-art-af91ab34aa454d4299f8ac9a67d42783 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-af91ab34aa454d4299f8ac9a67d427832025-08-20T03:39:05ZengWileyMediators of Inflammation0962-93511466-18612021-01-01202110.1155/2021/55235825523582Investigation of Newly Diagnosed Drug-Naive Patients with Systemic Autoimmune Diseases Revealed the Cleaved Peptide Tyrosine Tyrosine (PYY 3-36) as a Specific Plasma Biomarker of Rheumatoid ArthritisJozsef A. Balog0Agnes Kemeny1Laszlo G. Puskas2Szilard Burcsar3Attila Balog4Gabor J. Szebeni5Biological Research Centre, Szeged, HungaryDepartment of Medical Biology, University of Pecs, Pecs, HungaryBiological Research Centre, Szeged, HungaryDepartment of Rheumatology and Immunology, Faculty of Medicine, Albert Szent-Gyorgyi Health Centre, University of Szeged, Szeged, HungaryDepartment of Rheumatology and Immunology, Faculty of Medicine, Albert Szent-Gyorgyi Health Centre, University of Szeged, Szeged, HungaryBiological Research Centre, Szeged, HungaryThere is a current imperative to reveal more precisely the molecular pathways of early onset of systemic autoimmune diseases (SADs). The investigation of newly diagnosed drug-naive SAD patients might contribute to identify novel disease-specific and prognostic markers. The multiplex analysis of 30 plasma proteins in 60 newly diagnosed drug-naive SADs, such as RA (rheumatoid arthritis, n=31), SLE (systemic lupus erythematosus, n=19), and SSc (systemic scleroderma, n=10) patients, versus healthy controls (HCs, n=40) was addressed. Thirty plasma cytokines were quantified using the Procarta Plex™ panel. The higher expression of IL-12p40, IL-10, IL-13, IFN-γ, M-CSF, IL-4, NTproBNP, IL-17A, BMP-9, PYY (3-36), GITRL, MMP-12, and TNFRSF6 was associated with RA; IL-12p40, M-CSF, IL-4, GITRL, and NTproBNP were higher in SLE; or NTproBNP, PYY (3-36), and MMP-12 were increased in SSc over HCs, respectively. The cleaved peptide tyrosine tyrosine (PYY 3-36) was elevated in RA (361.6±47.7 pg/ml) vs. HCs (163.96±14.5 pg/ml, mean±SEM, ∗∗∗p=4×10−5). The CI (95%) was 268.05-455.16 pg/ml for RA vs. 135.55-192.37 pg/ml for HCs. The elevated PYY (3-36) level correlated significantly with the increased IL-4 or GITRL concentration but not with the clinical scores (DAS28, CRP, ESR, RF, aMCV). We are the first to report cleaved PYY (3-36) as a specific plasma marker of therapy-naive RA. Additionally, the multiplex plasma protein analysis supported a disease-specific cytokine pattern in RA, SLE, and SSc, respectively.http://dx.doi.org/10.1155/2021/5523582 |
| spellingShingle | Jozsef A. Balog Agnes Kemeny Laszlo G. Puskas Szilard Burcsar Attila Balog Gabor J. Szebeni Investigation of Newly Diagnosed Drug-Naive Patients with Systemic Autoimmune Diseases Revealed the Cleaved Peptide Tyrosine Tyrosine (PYY 3-36) as a Specific Plasma Biomarker of Rheumatoid Arthritis Mediators of Inflammation |
| title | Investigation of Newly Diagnosed Drug-Naive Patients with Systemic Autoimmune Diseases Revealed the Cleaved Peptide Tyrosine Tyrosine (PYY 3-36) as a Specific Plasma Biomarker of Rheumatoid Arthritis |
| title_full | Investigation of Newly Diagnosed Drug-Naive Patients with Systemic Autoimmune Diseases Revealed the Cleaved Peptide Tyrosine Tyrosine (PYY 3-36) as a Specific Plasma Biomarker of Rheumatoid Arthritis |
| title_fullStr | Investigation of Newly Diagnosed Drug-Naive Patients with Systemic Autoimmune Diseases Revealed the Cleaved Peptide Tyrosine Tyrosine (PYY 3-36) as a Specific Plasma Biomarker of Rheumatoid Arthritis |
| title_full_unstemmed | Investigation of Newly Diagnosed Drug-Naive Patients with Systemic Autoimmune Diseases Revealed the Cleaved Peptide Tyrosine Tyrosine (PYY 3-36) as a Specific Plasma Biomarker of Rheumatoid Arthritis |
| title_short | Investigation of Newly Diagnosed Drug-Naive Patients with Systemic Autoimmune Diseases Revealed the Cleaved Peptide Tyrosine Tyrosine (PYY 3-36) as a Specific Plasma Biomarker of Rheumatoid Arthritis |
| title_sort | investigation of newly diagnosed drug naive patients with systemic autoimmune diseases revealed the cleaved peptide tyrosine tyrosine pyy 3 36 as a specific plasma biomarker of rheumatoid arthritis |
| url | http://dx.doi.org/10.1155/2021/5523582 |
| work_keys_str_mv | AT jozsefabalog investigationofnewlydiagnoseddrugnaivepatientswithsystemicautoimmunediseasesrevealedthecleavedpeptidetyrosinetyrosinepyy336asaspecificplasmabiomarkerofrheumatoidarthritis AT agneskemeny investigationofnewlydiagnoseddrugnaivepatientswithsystemicautoimmunediseasesrevealedthecleavedpeptidetyrosinetyrosinepyy336asaspecificplasmabiomarkerofrheumatoidarthritis AT laszlogpuskas investigationofnewlydiagnoseddrugnaivepatientswithsystemicautoimmunediseasesrevealedthecleavedpeptidetyrosinetyrosinepyy336asaspecificplasmabiomarkerofrheumatoidarthritis AT szilardburcsar investigationofnewlydiagnoseddrugnaivepatientswithsystemicautoimmunediseasesrevealedthecleavedpeptidetyrosinetyrosinepyy336asaspecificplasmabiomarkerofrheumatoidarthritis AT attilabalog investigationofnewlydiagnoseddrugnaivepatientswithsystemicautoimmunediseasesrevealedthecleavedpeptidetyrosinetyrosinepyy336asaspecificplasmabiomarkerofrheumatoidarthritis AT gaborjszebeni investigationofnewlydiagnoseddrugnaivepatientswithsystemicautoimmunediseasesrevealedthecleavedpeptidetyrosinetyrosinepyy336asaspecificplasmabiomarkerofrheumatoidarthritis |